Targeting MUS81 promotes the anticancer effect of WEE1 inhibitor and immune checkpoint blocking combination therapy via activating cGAS/STING signaling in gastric cancer cells
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting MUS81 promotes the anticancer effect of WEE1 inhibitor and immune checkpoint blocking combination therapy via activating cGAS/STING signaling in gastric cancer cells
Authors
Keywords
-
Journal
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 40, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-10-10
DOI
10.1186/s13046-021-02120-4
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer Statistics, 2021
- (2021) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Lactobacillus rhamnosus GG induces cGAS/STING- dependent type I interferon and improves response to immune checkpoint blockade
- (2021) Wei Si et al. GUT
- Human MUS81: A Fence-Sitter in Cancer
- (2021) Sisi Chen et al. Frontiers in Cell and Developmental Biology
- Checkpoint molecules coordinately restrain hyperactivated effector T cells in the tumor microenvironment
- (2020) Min Yang et al. OncoImmunology
- Homologous recombination and Mus81 promote replication completion in response to replication fork blockage
- (2020) Benjamin Pardo et al. EMBO REPORTS
- Saccharomyces cerevisiae Mus81-Mms4 prevents accelerated senescence in telomerase-deficient cells
- (2020) Erin K. Schwartz et al. PLoS Genetics
- Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer
- (2020) Stephan B. Dreyer et al. GASTROENTEROLOGY
- Inhibition of DNA Repair in Cancer Therapy: Toward a Multi-Target Approach
- (2020) Samuele Lodovichi et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors
- (2020) Lulu Wang et al. JOURNAL OF CLINICAL INVESTIGATION
- Gastric cancer
- (2020) Elizabeth C Smyth et al. LANCET
- DNA Damage and Cancer Immunotherapy: A STING in the Tale
- (2020) Timo Reisländer et al. MOLECULAR CELL
- First-in-Human Trial of the Oral Ataxia Telangiectasia and Rad3-Related Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors
- (2020) Timothy A. Yap et al. Cancer Discovery
- PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response
- (2020) Chiho Kim et al. eLife
- Mus81-Eme1–dependent aberrant processing of DNA replication intermediates in mitosis impairs genome integrity
- (2020) Nicolás Luis Calzetta et al. Science Advances
- ATM inhibition enhances cancer immunotherapy by promoting mtDNA leakage and cGAS/STING activation
- (2020) Mengjie Hu et al. JOURNAL OF CLINICAL INVESTIGATION
- Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
- (2019) Triparna Sen et al. Cancer Discovery
- The DNA endonuclease Mus81 regulates ZEB1 expression and serves as a target of BET4 inhibitors in gastric cancer
- (2019) Yuping Yin et al. MOLECULAR CANCER THERAPEUTICS
- Optimizing adjuvant therapies for the treatment of gastric cancer: with a special focus on Asia
- (2019) Mitsuru Sasako Expert Review of Anticancer Therapy
- Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer
- (2019) Kyle C. Cuneo et al. JOURNAL OF CLINICAL ONCOLOGY
- ATR Protects the Genome against R Loops through a MUS81-Triggered Feedback Loop
- (2019) Dominick A. Matos et al. MOLECULAR CELL
- WEE1 kinase inhibitor AZD1775 induces CDK1 kinase-dependent origin firing in unperturbed G1- and S-phase cells
- (2019) Tatiana N. Moiseeva et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeted therapies in metastatic gastric cancer: Current knowledge and future perspectives
- (2019) Antonio Pellino et al. WORLD JOURNAL OF GASTROENTEROLOGY
- MUS81 Participates in the Progression of Serous Ovarian Cancer Associated With Dysfunctional DNA Repair System
- (2019) Renquan Lu et al. Frontiers in Oncology
- Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors. A COG Phase I Consortium Report (ADVL1312)
- (2019) Kristina A. Cole et al. CLINICAL CANCER RESEARCH
- The Integration of Radiotherapy With Immunotherapy for the Treatment of Non-Small Cell Lung Cancer
- (2018) Eric C. Ko et al. CLINICAL CANCER RESEARCH
- PD-1/PD-L1 pathway inhibitors in advanced prostate cancer
- (2018) Pedro Isaacsson Velho et al. Expert Review of Clinical Pharmacology
- Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer
- (2018) De-Shen Wang et al. GUT
- Non-canonical Activation of the DNA Sensing Adaptor STING by ATM and IFI16 Mediates NF-κB Signaling after Nuclear DNA Damage
- (2018) Gillian Dunphy et al. MOLECULAR CELL
- Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
- (2018) Tomas Jelinek et al. Frontiers in Immunology
- Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma
- (2017) Joseph P. Antonios et al. NEURO-ONCOLOGY
- MUS81 nuclease activity is essential for replication stress tolerance and chromosome segregation in BRCA2-deficient cells
- (2017) Xianning Lai et al. Nature Communications
- Human Tumor-Infiltrating Myeloid Cells: Phenotypic and Functional Diversity
- (2017) Louise A. Elliott et al. Frontiers in Immunology
- MUS81 is associated with cell proliferation and cisplatin sensitivity in serous ovarian cancer
- (2016) Suhong Xie et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer
- (2016) Yaqing Zhang et al. GUT
- The DNA Structure-Specific Endonuclease MUS81 Mediates DNA Sensor STING-Dependent Host Rejection of Prostate Cancer Cells
- (2016) Samantha S.W. Ho et al. IMMUNITY
- Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial
- (2016) Kei Muro et al. LANCET ONCOLOGY
- Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
- (2014) Antonella Sistigu et al. NATURE MEDICINE
- Inhibition of Mus81 by siRNA enhances sensitivity to 5-FU in breast carcinoma cell lines
- (2014) Ying Qian et al. OncoTargets and Therapy
- Selective tumor killing based on specific DNA-damage response deficiencies
- (2012) Michael Biss et al. CANCER BIOLOGY & THERAPY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Genomic instability — an evolving hallmark of cancer
- (2010) Simona Negrini et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now